Skip to main content

Table 3 Lack of anti-hyperalgesic effects by repeated systemic administration of antidepressants

From: Permanent relief from intermittent cold stress-induced fibromyalgia-like abnormal pain by repeated intrathecal administration of antidepressants

  n Pre
(sec)
P1
(sec)
P5
(sec)
P12
(sec)
Control-vehicle
(i.v.)
8 9.51 ± 0.22 9.80 ± 0.18 10.00 ± 0.29 9.57 ± 0.30
ICS-vehicle
(i.v.)
8 9.67 ± 0.23 5.78 ± 0.36 6.02 ± 0.12 6.36 ± 0.21
ICS- amitriptyline
(3 mg/kg, i.v.)
4 9.55 ± 0.42 5.85 ± 0.37 5.79 ± 0.36 6.72 ± 0.35
ICS-mianserin
(10 mg/kg, i.v.)
4 9.77 ± 0.34 5.14 ± 0.56 5.98 ± 0.39 6.66 ± 0.41
ICS- paroxetine
(1 mg/kg, i.v.)
4 9.34 ± 0.36 5.29 ± 0.34 6.89 ± 0.30 6.96 ± 0.65
ICS- milnacipran
(10 mg/kg, i.v.)
4 9.75 ± 0.47 6.25 ± 0.25 6.71 ± 0.21 7.54 ± 0.53
  1. Amitriptyline, mianserin, paroxetine or milnacipran were given intravenously (i.v.) and assessment of basal nociceptive thresholds was performed as described in Figure 5. Thermal pain threshold was assessed using the thermal paw withdrawal test. *p < 0.05, vs. vehicle-treated control group.